Health Care · Surgical & Medical Instruments & Apparatus

MMSI MERIT MEDICAL SYSTEMS INC SEC Filings & Insider Trading Activity 2026

company
CIK 856982118 filings
Russell 2000

MMSI at a glance

MERIT MEDICAL SYSTEMS INC (MMSI, SEC CIK 856982) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MERIT MEDICAL SYSTEMS INC (MMSI) reported revenue of $1.5 billion (up 11.8% from FY2024) and net income of $128.5 million. Diluted EPS was $2.13.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding MERIT MEDICAL SYSTEMS INC (MMSI) shares worth $2.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Lloyd Brian G. on November 16, 2026 of 16,722 shares at $86.33 per share.
  • In the last 90 days, MMSI insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.5B
+11.8% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$2.1M
13F holders
36 funds
$2.6B · +2 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: design, manufacture, and sell medical devices globally with emphasis on regulatory compliance and product lifecycle management
  • Regulatory challenges heightened by EU MDR certification delays, increased costs, and discontinuation of certain products in the E.U. this fiscal year
  • Strategic shift toward development of increasingly therapeutic medical products requiring more clinical trials, raising innovation risk and regulatory complexity
  • Notable compliance and risk exposure: expanded focus on global anti-bribery laws, extensive healthcare fraud and abuse scrutiny, and evolving privacy/data protection regulations impacting operations
  • Environmental and social governance risks addressed with potential impacts from PFAS and ethylene oxide sterilization restrictions and growing corporate social responsibility requirements

Risk Factors

  • Supply chain reliance on limited sterilization service providers risks production delays if any ceases operation or compliance, potentially halting sales
  • Geopolitical tensions in Ukraine, Middle East, Venezuela increasing supply interruptions, elevating cost pressures on petroleum-based materials critical to manufacturing
  • China’s Value-Based Purchasing (VBP) policy since 2022 negatively impacting pricing and revenue, with continued adverse effects expected in 2026
  • Competition from larger medical device firms and tech entrants with greater AI integration capabilities threatening market share and product relevance
  • CEO transition in Oct 2025 to Martha G. Aronson, with no key man insurance; potential disruption or loss of institutional knowledge poses material business risk

Management Discussion & Analysis

  • Revenue $1.516B in 2025, up 11.8% YoY ($159.4M increase from $1.357B in 2024), driven by U.S. and EMEA demand
  • Gross margin 48.7% in 2025 vs 47.4% in 2024; net income $128.5M (8.5% margin) vs $120.4M (8.9% margin)
  • Best segment: Cardiovascular sales $1.443B (+10.9%), operating income $166.1M; Worst: Endoscopy sales $72.9M (+33.0%), operating income $18.6M
  • Increased SG&A expenses by $55.5M (13.9%) and R&D by $9.9M (11.3%) in 2025; long-term debt $747.5M, contingent liabilities $4.5M, operating leases $87.5M
  • Management highlights multi-year Continued Growth initiatives through 2026; key risks include increased effective tax rate (24.8% vs 19.8%) and foreign currency fluctuations

AI summary of the MMSI 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $416.2M, up 8.4% YoY from $384.2M
  • Net margin 10.2% vs 7.2%; operating margin 14.1% vs 11.1% YoY
  • Best platform Endoscopy, $23.4M, up 32.9%; worst Procedural Solutions, $27.2M, down 15.9%
  • Cash $505.8M vs $448.5M; operating cash flow $175.2M vs $198.9M
  • View Point sales launched; 2026 capital spending expected at $60M to $70M, with supply delays and tariff risks തുടര

Risk Factors

  • Newly added geopolitical risk: U.S.-Israel-Iran conflict escalation threatens energy supplies, supply chains, and petroleum-based input costs
  • Most materially updated financial risk: $700 million revolving commitment may increase leverage-covenant pressure and reduce cash for operations
  • Debt compliance risk: covenant breach could accelerate $747.5 million of 3.00% Convertible Notes due 2029
  • Operational risk: higher resin and petroleum-based material costs from disrupted global energy markets
  • Liquidity risk: secured-credit-agreement default could trigger collateral foreclosure and impair capital-expenditure funding

AI summary of the MMSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 earnings release for quarter ended September 30, 2026
  • Results and management commentary available in Exhibit 99.1, relevant for updating revenue, profitability and outlook expectations

Item 7.01: Regulation FD Disclosure

  • Q3 2026 results covered quarter ended September 30, 2026, with conference call and presentation on October 29, 2026
  • Solo Pace acquisition closed October 13, 2026 for approximately $45 million cash

Item EX-99.2: Item EX-99.2

  • Q3 revenue $416.2M, up 8.4% year over year, with domestic growth of 11.0% outpacing international growth of 4.4%
  • GAAP operating margin 14.1% versus 11.1%, while net income rose 52.4% to $42.3M and EPS increased 51.3% to $0.70

Item EX-99.1: Item EX-99.1

  • Q3 revenue $416.2M, up 8.4%, with 9% organic constant-currency growth, signaling broad underlying demand strength
  • GAAP operating margin 14.1% vs 11.1%, while non-GAAP margin reached 21.3% vs 19.7%, indicating improved operating leverage

Item EX-99.3: Item EX-99.3

  • Merit acquired Solo Pace’s remaining equity on October 13, 2026 for approximately $45 million, following its prior 18% ownership
  • Adds proprietary temporary pacing systems for TAVR and other transcatheter heart-valve procedures to Merit’s Cardiac Therapies platform
Filed Aug 20, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • COO role eliminated; Neil Peterson became Senior Advisor and resigns effective March 5, 2027 for good reason
  • Sheri Lewis appointed Executive Vice President of Global Operations effective August 31, 2026

Item EX-99.1: Item EX-99.1

  • Sheri Lewis joins as Executive Vice President of Global Operations on August 31, 2026
  • Leadership transition targets supply-chain execution, product availability, and global operational scaling

Item 7.01: Regulation FD Disclosure

  • Press release announces a global operations leadership transition at Merit Medical
  • Leadership change may affect manufacturing execution, supply continuity and operational strategy
Filed Jul 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $418.8M, up 10%; organic constant-currency growth 9%, signaling broad-based demand acceleration
  • Non-GAAP operating margin 22.6% vs 21.2%; GAAP EPS $0.65, up 20%, demonstrating strong operating leverage

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Merit Medical’s operating and financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed earnings release for investor review

Item 7.01: Regulation FD Disclosure

  • Q2 2026 results conference call scheduled for July 30, covering the quarter ended June 30, 2026
  • Earnings press release and presentation furnished as Exhibits 99.1 and 99.2

Item EX-99.1#2: Item EX-99.1#2

  • Q2 revenue $418.8M, up 9.5%, with domestic growth 11.0% and international growth 7.3%
  • GAAP operating margin 14.4% versus 12.3%, while EPS rose 20.3% to $0.65

AI summaries of MMSI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MMSI

Don't miss the next MMSI filing

  • Alerts as it files. A push when MMSI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MMSI, by share count.
  • Ask anything. An AI agent that reads every MMSI filing and answers with sources.

MMSI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lloyd Brian G.MNov 16, 2026$37.71
Lloyd Brian G.MNov 16, 2026-
Lloyd Brian G.SellNov 16, 2026$86.33
Lewis SheriASep 4, 2026-
Voigt Michel J.GAug 24, 2026-
Peterson Neil W.SellAug 24, 2026$90.45
Peterson Neil W.SellAug 4, 2026$85.00
Voigt Michel J.GJun 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.4B$1.5B
Gross Profit-$643.3M$738.3M
Operating Income-$155.7M$184.7M
Net Income-$120.4M$128.5M
Gross Margin-47.4%48.7%
Op. Margin-11.5%12.2%
Net Margin-8.9%8.5%
Balance Sheet
Total Assets$2.3B$2.4B$2.7B
Equity$1.2B$1.4B$1.6B
ROE-8.7%8.1%
Per Share
EPS-$2.03$2.13
Cash Flow
Operating CF-$220.8M$297.4M
CapEx-$35.1M$81.7M

Source: XBRL data in MERIT MEDICAL SYSTEMS INC (MMSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MMSI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MMSI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$2.55B
Q2 202634$2.18B
Q1 202636$2.10B
Q4 202531$2.80B
Q3 202533$2.70B
Q2 202533$3.23B
Q1 202532$2.56B
Q4 202430$1.88B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 265 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MMSI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Sep 9, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
8-KAug 20, 2026Analysis-
4Aug 5, 2026--
10-QJul 30, 2026Analysis
8-KJul 30, 2026Analysis-
4Jun 17, 2026--
4Jun 8, 2026-
4May 21, 2026-
4May 19, 2026-
4May 19, 2026-
4May 19, 2026-
4May 19, 2026-
4May 19, 2026-
8-KMay 19, 2026Analysis
4May 19, 2026-
4May 19, 2026-
4May 11, 2026-
4May 11, 2026-
4May 7, 2026-
4May 7, 2026-

Related Health Care companies

All Health Care →

MMSI SEC filings: frequently asked questions

Are MMSI insiders buying or selling?

In the last 90 days, MERIT MEDICAL SYSTEMS INC (MMSI) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MMSI stock?

As of September 30, 2026, the largest MERIT MEDICAL SYSTEMS INC (MMSI) holders among the 13F filers tracked by SignalX were BlackRock ($818.5 million), Vanguard Portfolio Management LLC ($295.1 million), Vanguard Capital Management LLC ($223.4 million), State Street Corp ($211.9 million), Dimensional Fund Advisors ($142.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MMSI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MERIT MEDICAL SYSTEMS INC (MMSI) reported revenue of $1.5 billion (up 11.8% from FY2024) and net income of $128.5 million. Diluted EPS was $2.13. The figures come from the XBRL data in the 10-K.

What are the main risks in MMSI's latest 10-K?

In the 10-K filed February 24, 2026, MERIT MEDICAL SYSTEMS INC (MMSI) flagged: Supply chain reliance on limited sterilization service providers risks production delays if any ceases operation or compliance, potentially halting sales. Geopolitical tensions in Ukraine, Middle East, Venezuela increasing supply interruptions, elevating cost pressures on petroleum-based materials critical to manufacturing. (AI summary of the Risk Factors section.)

What did MMSI report in its latest 8-K?

MERIT MEDICAL SYSTEMS INC (MMSI) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 earnings release for quarter ended September 30, 2026.

What are the latest MMSI SEC filings?

MERIT MEDICAL SYSTEMS INC (MMSI) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.

What is MMSI's SEC CIK number?

MERIT MEDICAL SYSTEMS INC (MMSI)'s SEC Central Index Key (CIK) is 856982. EDGAR lists every MMSI filing under that number.

Ask anything about MMSI

The research agent reads MMSI's filings, financials, insider trades and 13F holders, then answers with sources.